Lysiac and Lysiac Institute work on a wide range of policy projects. These projects are guided by a shared objective, sometimes requiring creative solutions to achieve it. Examples include:
Dutch DO-BO provides a structured and reliable kick-start for pharmacotherapeutic (FT) dossier writing, aligned with the template of Zorginstituut Nederland (ZIN). It supports the development of reimbursement dossiers by efficiently structuring relevant information, allowing teams more room for strategy and refinement.
The core
This results in a kick-start PT dossier: a solid starting point that reduces drafting time and effort.
Data security and confidentiality
DO-BO has been developed in collaboration with MArS and is available for various types of clinical dossiers.
For more information: info@lysiac.nl
The AccessWijzer is a knowledge test and research survey among healthcare professionals, focusing on topics related to health technology assessment (HTA), reimbursement, and market access in the Netherlands. The survey includes specialists and hospital pharmacists and is conducted among the large and active medical panel of Samhealth.
The core
The outcomes provide starting points for dialogue on reimbursement and access and support knowledge development in practice.
Interested in participating or would you like to know more?
Please contact info@lysiac.nl or info@samhealth.nl.
Download the PDF here
The Lysiac DataBase tracks key information on package assessments and the course of reimbursement procedures in the Netherlands. The database contains information on medicines that have undergone a reimbursement procedure, including product characteristics, the assessment, procedural steps, duration and outcomes.
The core
The Lysiac DataBase provides relevant information on real-world cases and reimbursement outcomes and forms a solid basis for analysis and insight into policy trends, with comparable cases offering guidance for the approach to current reimbursement questions.
For more information: info@lysiac.nl
Lysiac provides short analyses of key public committee meetings and policy developments in the area of market access and reimbursement in the Netherlands. The analyses combine factual information with interpretation, focused on practical application.
The core
The analyses provide access to relevant policy information and form a solid basis for decision-making, strategic choices and further action.
For more information: info@lysiac.nl
Evelien Yap has been a partner at Lysiac since 2011 and specialises in reimbursement and access to treatments.
Trained as a pharmacist and holding a master’s degree in health services research, she brings extensive experience from the pharmaceutical industry. Evelien has in-depth expertise in market access, pricing and reimbursement, health economics, negotiations and stakeholder engagement. Combining strategic insight with deep expertise in reimbursement systems and policy developments, underpinned by experience in regulatory affairs, she ensures sound justification for patient access.
Evelien is dedicated to achieving optimal patient access to treatments, guided by an innovative mindset and a strong commitment to quality and integrity.
Lysiac was founded in 2010 by Bart van der Lelie, a specialist in healthcare policy. With a background in molecular biology, he works at the intersection of science, policy and practice. He has management experience in the pharmaceutical industry in the areas of HTA, pricing, government relations and communication.
Throughout his career, Bart has been directly involved in policy developments, including as a member of technical consultation of the Dutch Healthcare Authority (NZa) and as chair of various committees and umbrella organisations. By structurally attending and analysing public committee meetings of the House of Representatives, ACP and Zorginstituut Nederland, and by maintaining close contact with stakeholders in the field, he focuses on workable solutions. His goal remains timely access to appropriate treatments for patients.
